<DOC>
	<DOCNO>NCT02487706</DOCNO>
	<brief_summary>Data capacity hemodialysis remove dolutegravir ( DTG ) plasma patient end-stage renal disease ( ESRD ) hemodialysis ( HD ) lacking . If DTG remove plasma HD , would possible subtherapeutic drug concentration end HD session .</brief_summary>
	<brief_title>Assessment Dolutegravir Removed Hemodialysis HIV-infected Patients With End-stage Renal Disease</brief_title>
	<detailed_description>The prevalence chronic renal disease end-stage renal disease ( ESRD ) increase HIV-positive population . This mean increase number HIV-infected patient need renal replacement therapy.However , little known DTG removal plasma HD patient ESRD . Objective : evaluate effect HD DTG clearance well DTG plasma concentration steady state HIV-infected patient ESRD undergo HD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 1 year old old . 2 . HIV document infection ( western blot ) 3 . ESRD undergoing routine hemodialysis 4 . Stable antiretroviral treatment ( change within prior 2 week ) 5 . Signature inform consent 1 . Inadequate adherence antiretroviral treatment ( &lt; 90 % week prior inclusion ) . 2 . Clinical evidence suspicion patient able comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>HIV-infection</keyword>
</DOC>